A 26-Week, Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Response to Treatment (ACR50 [American College of Rheumatology 50% response criteria]) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-Interleukin-1beta Monoclonal Antibody) [canakinumab] Plus MTX [methotrexate] as Compared to MTX Alone in Early Rheumatoid Arthritis Patients.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Canakinumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Novartis
- 27 Aug 2010 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
- 27 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.